Drug Profile
Research programme: antisense therapeutics - Bristol-Myers Squibb/OliPass
Latest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator OliPass
- Developer Bristol-Myers Squibb; OliPass
- Class Antisense oligonucleotides; Peptide nucleic acids
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 24 Jul 2023 Discontinued - Preclinical for Unspecified in South Korea (unspecified route)
- 24 Jul 2023 Discontinued - Preclinical for Unspecified in USA (unspecified route)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Unspecified in South Korea